Navigation Links
Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
Date:12/14/2010

NEW BRUNSWICK, N.J., Dec. 14, 2010 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transformational contributions toward the improvement of human health.  Nominations are available at www.pauljanssenaward.com and will be accepted until February 15, 2011, for consideration by an independent selection committee of world renowned scientists. The winner or winners will receive a $100,000 cash prize.

The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), who is widely recognized as one of the most productive scientists of the 20th century. Known by colleagues throughout the scientific community as "Dr. Paul," Janssen was responsible for breakthrough treatments in disease areas including pain management, psychiatry, infectious disease and gastroenterology and founded Janssen Pharmaceutica, N.V., a Johnson & Johnson Company.

"The Dr. Paul Janssen Award for Biomedical Research recognizes outstanding scientists whose work is game-changing in the development or delivery of critical new treatments and exemplifies Dr. Paul's passion for medical innovation," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson, who worked for many years alongside Dr. Janssen.

In September 2010, the Award was presented to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and Erik De Clercq, M.D., Ph.D., chairman of the Department of Microbiology and Immunology of the Medical School at the Catholic University of Leuven. Dr. Fauci received the Award for his ground-breaking contributions to basic and clinical research in the areas of AIDS and other immunodeficiencies. Dr. De Clercq was recognized for his landmark discoveries in anti-HIV medications, including nucleotide analogues, and inventions or co-inventions of six approved drugs for anti-viral therapy.

Previous Award winners include Axel Ullrich, Ph.D., director, Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany; Professor Marc Feldmann, FMedSci, FAA, FRS, and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS, of the Kennedy Institute of Rheumatology, Imperial College London; and Craig Mello, Ph.D., Nobel Laureate, of the Howard Hughes Medical Institute and University of Massachusetts Medical School.

"Scientists across the globe work tirelessly to achieve significant and lasting contributions to improving health and well being," said Harlan Weisman, M.D., chief science and technology officer, Medical Devices & Diagnostics, Johnson & Johnson. "In acknowledging and rewarding those contributions, The Dr. Paul Janssen Award inspires us all to embody the scientific passion, compassion and leadership for which Dr. Paul was so well loved and respected."

Beyond the passion and creativity Dr. Paul demonstrated in the laboratory, he also inspired and mentored many young scientific leaders who went on to great achievements in addressing medical need.

"As in past years, we look forward to selecting a 2011 Dr. Paul Janssen Award winner from among the nominations of worthy individuals in research institutions and companies around the world, who has significantly improved human health through dedication to the advancement of science and medicine," said Solomon Snyder, Ph.D., distinguished service professor of neuroscience, pharmacology and psychiatry, Johns Hopkins School of Medicine and 2011 chair of the Dr. Paul Janssen Award Selection Committee.

The 2011 Dr. Paul Janssen Award winner will be announced in the second half of 2011.

About The Dr. Paul Janssen Award for Biomedical ResearchEstablished by Johnson & Johnson, The Dr. Paul Janssen Award salutes the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Dr. Paul Janssen Award is named for Dr. Paul Janssen, who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen was one of the 20th century's most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.

About Johnson & Johnson Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,400 employees at more than 250 Johnson & Johnson companies work with partners in healthcare to touch the lives of over a billion people every day, throughout the world.Contact:Seema KumarJohnson & Johnson Pharmaceutical Research & Development, L.L.C.908-218-6460 or skumar10@its.jnj.comFrederik WittockJohnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V.+32 14 60 57 24 or fwittock@its.jnj.com
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
7. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
10. Samplifys AutoFocus™ Beamforming Technology Awarded Electronic Designs Best of 2010
11. Zimmer Awarded Premium Pricing for Trabecular Metal™ Modular Cup in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):